- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07695493
Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis (PREVI)
An Open-label Randomized Trial Evaluating the Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The HIV/AIDS epidemic remains uncontrolled in France, with approximately 5,000 to 6,000 new cases reported each year. Since January 2016, HIV pre-exposure prophylaxis (PrEP)-which involves taking a single oral tablet containing two antiretroviral drugs-has been available in France. The effectiveness of this PrEP has been demonstrated, with a relative reduction in HIV incidence of nearly 97% when PrEP is taken correctly.
However, only nearly 50,000 people are using PrEP in France in 2024, which is far short of the targets needed to control the epidemic. Indeed, the population of men who have sex with men (MSM) at risk of HIV infection is estimated at over 200,000, and the number of heterosexuals on PrEP is negligible, even though 40% of new HIV diagnoses involve heterosexuals from countries with high prevalence (Sub-Saharan Africa).
Furthermore, these 50,000 people on PrEP represent only 64% of the >120,000 people who have started PrEP since 2016, indicating that many have discontinued this prophylaxis over time. One of the challenges in implementing PrEP stems from the small number of trained hospital and primary care physicians and their limited time availability to provide a PrEP care.
Since 2022, PrEP training programs in medical settings, involving nurses, have been implemented to train them to monitore people on PrEP. This involvement of nurses would help increase the availability of PrEP, free up doctors' time for complex cases, and enhance the value of nursing work.
However, there has been no evaluation of this care provided by nurses to people on PrEP in terms of quality, acceptability, satisfaction among people on PrEP, nurses, and doctors, or its cost-effectiveness.
The aim of our study is therefore to assess whether the care provided to subjects on PrEP by these nurses is as good, well-accepted, and satisfactory for subjects and caregivers as it would be if the care were provided solely by physicians.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jérôme Lambert, MD PhD
- Telefonnummer: +33 0142499742
- E-Mail: jerome.lambert@u-paris.fr
Studieren Sie die Kontaktsicherung
- Name: Bénédicte Loze, Nurse
- Telefonnummer: +33 01.42.49.48.52
- E-Mail: benedicte.loze@aphp.fr
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Male sex assigned at birth, aged ≥ 18 years
- Individual at risk of HIV infection
- Currently receiving PrEP care and willing to continue follow-up in a hospital setting
- Receiving care at a hospital setting by a physician and not objecting to follow-up by a nurse
- Having received complete information about the study and having provided a free written informed consent
- Affiliated with a social security system (beneficiary or entitled individual) or covered by State Medical Aid (AME).
Exclusion Criteria:
- Individual with confirmed HIV infection
- Currently receiving nurse care in a hospital setting
- Having renal impairment (creatinine clearance < 60 mL/min)
- Unable to provide informed consent
- Not affiliated with a social security system or not covered by State Medical Aid (AME)
- Under legal guardianship or curatorship
- Deprived of liberty by judicial or administrative decision, or individuals receiving psychiatric care under Article L1121-6 of the French Public Health Code
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Follow-up visits for PrEP prescription conducted by a physician.
|
Monitoring of PrEP by physicians
|
|
Experimental: Follow-up visits for PrEP prescription conducted by a nurse under the same conditions.
|
Monitoring of PrEP by nurses
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Compliance to PrEP
Zeitfenster: Up to 12 months
|
Compliance to PrEP is defined by a composite criterion comprising:
|
Up to 12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Occurrence of sexually transmitted infection (STI)
Zeitfenster: At baseline
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At baseline
|
|
Occurrence of sexually transmitted infection (STI)
Zeitfenster: At 6 months
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At 6 months
|
|
Occurrence of sexually transmitted infection (STI)
Zeitfenster: At 12 months
|
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
|
At 12 months
|
|
Tolerability of PrEP
Zeitfenster: At baseline
|
Plasma creatine level
|
At baseline
|
|
Tolerability of PrEP
Zeitfenster: At 6 months
|
Plasma creatine level
|
At 6 months
|
|
Tolerability of PrEP
Zeitfenster: At 12 months
|
Plasma creatine level
|
At 12 months
|
|
PrEP adherence
Zeitfenster: At 12 months
|
Number of patient visits completed during the year and Tenofovir diphosphate concentrations
|
At 12 months
|
|
Treatment acceptability among participants
Zeitfenster: Up to 12 months
|
Number of participants who discontinued follow-up and reasons for discontinuation
|
Up to 12 months
|
|
Incidence of HIV infection
Zeitfenster: Up to 12 months
|
HIV infection during follow up (positive serology or HIV RNA)
|
Up to 12 months
|
|
Cost of care
Zeitfenster: Up to 12 months
|
From the perspectives of the healthcare system, patients, and health insurance : Incremental or decremental cost-effectiveness ratio (Cost per patient, Time spent in consultations, Number of prescribed labs and tests, and Number and duration of any hospitalizations…)
|
Up to 12 months
|
|
Patient and caregiver satisfaction
Zeitfenster: At 12 months
|
Focus groups
|
At 12 months
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Durch Blut übertragene Infektionen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des Immunsystems
- Infektionen
- RNA-Virusinfektionen
- Viruserkrankungen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- HIV-Infektionen
Andere Studien-ID-Nummern
- APHP230860
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .